Investigation of the ameliorative effects of amygdalin against arsenic trioxide-induced cardiac toxicity in rat

AMG, recognized as vitamin B17, is celebrated for its antioxidant and anti-inflammatory prowess, which underpins its utility in averting disease and decelerating the aging process. This study ventures to elucidate the cardioprotective mechanisms of amygdalin against ATO-induced cardiac injury, with a spotlight on the AMPK and SIRT1 signaling cascade. Employing a Sprague-Dawley rat model, we administered amygdalin followed by ATO and conducted a 15-day longitudinal study. Our findings underscore the ameliorative impact of amygdalin on histopathological cardiac anomalies, a reduction in cardiac biomarkers, and an invigoration of antioxidant defenses, thereby attenuating oxidative stress and inflammation. Notably, amygdalin's intervention abrogated ATO-induced apoptosis and inflammatory cascades, modulating key proteins along the AMPK/SIRT1 pathway and significantly dampening inflammation. Collectively, these insights advocate for amygdalin's role as a guardian against ATO-induced cardiotoxicity, potentially through the activation of the AMPK/SIRT1 axis, offering a novel therapeutic vista in mitigating oxidative stress, apoptosis, and inflammation. • Amygdalin's Antioxidant and Anti-Inflammatory Effects. • Cardioprotective Mechanisms Against Arsenic Trioxide (ATO). • Histopathological and Biomarker Improvements. • Modulation of AMPK/SIRT1 Pathway and Inflammation Reduction.